Hyperlipidemia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 139 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperlipidemia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H1 2015', provides an overview of the Hyperlipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hyperlipidemia Overview 11
Therapeutics Development 12
Pipeline Products for Hyperlipidemia - Overview 12
Pipeline Products for Hyperlipidemia - Comparative Analysis 13
Hyperlipidemia - Therapeutics under Development by Companies 14
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 17
Hyperlipidemia - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Hyperlipidemia - Products under Development by Companies 22
Hyperlipidemia - Products under Investigation by Universities/Institutes 25
Hyperlipidemia - Companies Involved in Therapeutics Development 26
Ahn-Gook Pharmaceutical Co., Ltd. 26
Alnylam Pharmaceuticals, Inc. 27
Amgen Inc. 28
BCWorld Pharm Co. Ltd. 29
Catabasis Pharmaceuticals, Inc. 30
CJ CheilJedang Corp. 31
CrystalGenomics, Inc. 32
Daewoong Pharmaceutical Co., Ltd. 33
Eli Lilly and Company 34
Esperion Therapeutics, Inc. 35
HanAll Biopharma Co., Ltd. 36
Hanmi Pharmaceuticals, Co. Ltd. 37
Huons Co., Ltd. 38
Isis Pharmaceuticals, Inc. 39
Jeil Pharmaceutical Co., Ltd. 40
LG Life Sciences, Ltd. 41
Michigan Life Therapeutics, LLC 42
Pfizer Inc. 43
Pharmena SA 44
Piramal Enterprises Limited 45
Prometheon Pharma, LLC 46
Protalix BioTherapeutics, Inc. 47
Regeneron Pharmaceuticals, Inc. 48
TSH Biopharm Corporation Limited 49
Yuhan Corporation 50
Hyperlipidemia - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
(atorvastatin calcium + losartan potassium) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(atorvastatin calcium + metformin) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
(gemigliptin + rosuvastatin calcium) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
(rosuvastatin calcium + metformin SR) - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
(rosuvastatin calcium + telmisartan) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AGSAA-010 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ALN-ANG - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BCWPC-001 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
bempedoic acid - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
bococizumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
BSN-272 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CAT-2000 Series - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CAT-2003 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CG-301269 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
CSN-501 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
DWJ-1330 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
DWJ-1351 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
etanercept biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
evolocumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
gemcabene calcium - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
HCP-1007 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
HU-012 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ISIS-ANGPTL3Rx - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
JLP-1302 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
JLP-1401 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
LY-3015014 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
N-11 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
P-7435 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
PF-06427878 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
REGN-1001 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
S-0101870 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecule for Hyperlipidemia - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
TRIA-662 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Hyperlipidemia - Recent Pipeline Updates 106
Hyperlipidemia - Dormant Projects 123
Hyperlipidemia - Discontinued Products 129
Hyperlipidemia - Product Development Milestones 130
Featured News & Press Releases 130
Nov 18, 2014: Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 130
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 132
Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 135
Mar 05, 2014: Esperion Therapeutics Provides ETC-1002 Program Update 135
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 136
Mar 19, 2010: FDA warns about increased risk of muscle injury with Zocor. 136
Mar 27, 2003: Zocor selected as sole high-potency HMG agent for U.S. Department of Veteran Affairs and Department of Defense. 136
Nov 05, 1998: Merck announces get-to-goal guarantee for patients taking cholesterol-lowering drug Zocor 136
Jul 05, 1995: FDA clears Merck's Zocor to save lives, prevent heart attacks; Zocor is first cholesterol-lowering drug available for this use 137
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 138
Disclaimer 139

List of Tables
Number of Products under Development for Hyperlipidemia, H1 2015 12
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Hyperlipidemia - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 26
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 27
Hyperlipidemia - Pipeline by Amgen Inc., H1 2015 28
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2015 29
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 30
Hyperlipidemia - Pipeline by CJ CheilJedang Corp., H1 2015 31
Hyperlipidemia - Pipeline by CrystalGenomics, Inc., H1 2015 32
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 33
Hyperlipidemia - Pipeline by Eli Lilly and Company, H1 2015 34
Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2015 35
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 36
Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 37
Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2015 38
Hyperlipidemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 39
Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 40
Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H1 2015 41
Hyperlipidemia - Pipeline by Michigan Life Therapeutics, LLC, H1 2015 42
Hyperlipidemia - Pipeline by Pfizer Inc., H1 2015 43
Hyperlipidemia - Pipeline by Pharmena SA, H1 2015 44
Hyperlipidemia - Pipeline by Piramal Enterprises Limited, H1 2015 45
Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2015 46
Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 47
Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 48
Hyperlipidemia - Pipeline by TSH Biopharm Corporation Limited, H1 2015 49
Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2015 50
Assessment by Monotherapy Products, H1 2015 51
Assessment by Combination Products, H1 2015 52
Number of Products by Stage and Target, H1 2015 54
Number of Products by Stage and Mechanism of Action, H1 2015 56
Number of Products by Stage and Route of Administration, H1 2015 58
Number of Products by Stage and Molecule Type, H1 2015 60
Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2015 106
Hyperlipidemia - Dormant Projects, H1 2015 123
Hyperlipidemia - Dormant Projects (Contd..1), H1 2015 124
Hyperlipidemia - Dormant Projects (Contd..2), H1 2015 125
Hyperlipidemia - Dormant Projects (Contd..3), H1 2015 126
Hyperlipidemia - Dormant Projects (Contd..4), H1 2015 127
Hyperlipidemia - Dormant Projects (Contd..5), H1 2015 128
Hyperlipidemia - Discontinued Products, H1 2015 129